menu search

ELYM / See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting
Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically significant separation from placebo on the trial's primary endpoint of daily pain score. The Company will longer pursue the. Read More
Posted: Apr 25 2022, 09:06
Author Name: Benzinga
Views: 102533

ELYM News  

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

By Zacks Investment Research
July 21, 2023

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises more_horizontal

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

By InvestorPlace
July 20, 2023

Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?

Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. more_horizontal

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

By Market Watch
July 20, 2023

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal ex more_horizontal

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

By GlobeNewsWire
November 30, 2022

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology compa more_horizontal

Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic

By GeekWire
April 25, 2022

Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic

Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data. more_horizontal

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

By Benzinga
April 25, 2022

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

Eliem Therapeutics Inc's (NASDAQ: ELYM) ETX-810 Phase 2a trial in diabetic peripheral neuropathic pain (DPNP) failed to achieve statistically signif more_horizontal

Eliem Therapeutics to Present at Stifel's 2022 CNS Days

By GlobeNewsWire
March 21, 2022

Eliem Therapeutics to Present at Stifel's 2022 CNS Days

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology comp more_horizontal


Search within

Pages Search Results: